当前位置： SCI文献检索 > JOURNAL OF THROMBOSIS AND THROMBOLYSIS期刊下所有文献 > Bleeding complications in venous thrombosis patients on well-managed warfarin.

Bleeding complications in venous thrombosis patients on well-managed warfarin.

Abstract：

:Anticoagulation treatment is effective in preventing both death and recurrence in patients with venous thromboembolism (VTE), but at the same time confers a substantial risk of bleeding complications. The aim of this study was to examine the rate of and predictors for bleeding complications in VTE patients on warfarin with high treatment quality. In total 13,859 patients on warfarin for VTE between January 1st 2006 and December 31th 2011 were retrieved from the national quality register Auricula. The cohort was matched with the Swedish National Patient Register for complications and background characteristics, the Cause of Death Register for date and cause of death and the Swedish Prescribed Drug Register for retrieved medication. The rate of major bleeding was 2.36 per 100 treatment years, increasing with age from 1.25 to 4.33 for those under 60 or over 80 years of age, respectively. Factors found to independently increase the risk of bleeding complications were increasing age HR 1.02, cardiac failure HR 1.39, Chronic pulmonary disease HR 1.41, alcohol abuse HR 3.33, anaemia HR 1.75, hypertension HR 1.29 and a history of major bleeding HR 1.69. Warfarin as treatment for VTE is safe with a low rate of bleeding complications at least for the younger patient. In an era of NOAK, warfarin has a comparable safety profile among VTE patients and is still a valid treatment option.

journal_name

J Thromb Thrombolysis

journal_title

Journal of thrombosis and thrombolysis

authors

Sandén P,Renlund H,Svensson PJ,Själander A

doi

10.1007/s11239-015-1305-4

subject

Has Abstract

pub_date

2016-02-01 00:00:00

pages

351-8

issue

2

eissn

0929-5305

issn

1573-742X

pii

10.1007/s11239-015-1305-4

journal_volume

41

pub_type

杂志文章

相关文献

JOURNAL OF THROMBOSIS AND THROMBOLYSIS文献大全
  • A dose-finding clinical trial of staphylokinase SY162 in patients with long-term venous access catheter thrombotic occlusion.

    abstract：BACKGROUND:We investigated the safety and efficacy of several dosing regimens of catheter-directed staphylokinase (SY162) bolus administration for the treatment of long-term venous access catheter occlusion. METHODS:This open-label, ascending dose study enrolled 24 subjects. Three doses of SY162 were evaluated in thre...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 临床试验,杂志文章

    doi：10.1007/s11239-006-0006-4

    authors： Verhamme P,Goossens G,Maleux G,Collen D,Stas M

    更新日期：2007-08-01 00:00:00

  • Structure-function relationships of factor Xa inhibitors: implications for the practicing clinician.

    abstract：:The recent development and approval of novel oral anticoagulants represents a significant success in the intelligent design of target-specific therapeutics. However, while these agents obviate many of the shortcomings of their predecessor (warfarin), they present novel challenges in pharmacologic management as well. E...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,评审

    doi：10.1007/s11239-013-0991-z

    authors： Steinberg BA,Becker RC

    更新日期：2014-01-01 00:00:00

  • Exposure to platelets promotes functional properties of endothelial progenitor cells.

    abstract：:Recent evidence indicates that endothelial progenitor cells (EPCs) have an important role in the process of repair following vascular injury, and that platelets mediate their recruitment to sites of injury. Platelets and EPCs can interact and bind directly. However, there is limited information on the effect of platel...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-010-0514-0

    authors： Leshem-Lev D,Omelchenko A,Perl L,Kornowski R,Battler A,Lev EI

    更新日期：2010-11-01 00:00:00

  • Acquired thrombotic thrombocytopenic purpura: puzzles, curiosities and conundrums.

    abstract：:We report a case of acquired thrombotic thrombocytopenic purpura (TTP) in a 34-year old patient with a prior diagnosis of systemic lupus erythematosis (SLE) who was recently started on hydroxychloroquine. Presenting symptoms included fevers, sore throat and productive cough with progressive weakness, dyspnea on exerti...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-010-0517-x

    authors： Mar N,Mendoza Ladd A

    更新日期：2011-01-01 00:00:00

  • Bleeding complications after contemporary pharmacoinvasive therapy for ST elevation myocardial infarction.

    abstract：BACKGROUND:Pharmacoinvasive therapy for the treatment of ST elevation myocardial infarction (STEMI) is a strategy that combines early restoration of coronary flow via pharmacologically induced thrombolysis with subsequent, prompt percutaneous coronary intervention (PCI). Prior studies suggesting a heightened bleeding r...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-005-0344-7

    authors： Gutierrez MJ,Aggarwal A,Gilbert K,Sobel BE,Dauerman HL

    更新日期：2004-12-01 00:00:00

  • Clinical implications of elevated PAI-1 revisited: multiple arterial thrombosis in a patient with essential thrombocythemia and elevated plasminogen activator inhibitor-1 (PAI-1) levels: a case report and review of the literature.

    abstract：:Plasminogen activator inhibitor (PAI-1), a member of the serine protein family, is the most active in vivo inhibitor of fibrinolysis induced by plasminogen, tissue plasminogen activator (tPA), and urokinase type plasminogen activator (uPA). While the association between elevated PAI-1 and thrombogenesis has been well ...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,评审

    doi：10.1023/a:1008907001042

    authors： Senno SL,Pechet L

    更新日期：1999-08-01 00:00:00

  • A Randomized, Blinded Study of Two Doses of Novastan(R) (Brand of Argatroban) Versus Heparin as Adjunctive Therapy to Recombinant Tissue Plasminogen Activator (Accelerated Administration) in Acute Myocardial Infarction: Rationale and Design of the Myocard

    abstract：:Thrombolytic therapy has become a standard treatment for selected patients with acute myocardial infarction (MI). Various thrombolytic agents have been shown to decrease mortality. However, current thrombolytic agents still suffer significant shortcomings, such as a low optimal reperfusion rate delayed reperfusion. an...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1023/a:1008872031770

    authors： Serebruany VL,Jang IK,Giugliano RP,Massey TJ,Schwarz Jr RP

    更新日期：1998-01-01 00:00:00

  • Sulfonylureas are not associated with increased mortality in diabetics treated with thrombolysis for acute myocardial infarction.

    abstract：BACKGROUND:Sulfonylurea compounds may impair ischemic preconditioning and endogenous fibrinolysis. Increased mortality has been reported in diabetics receiving these drugs prior to admission for acute myocardial infarction when treated by direct angioplasty. Although thrombolytics are currently employed far more freque...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1023/a:1012979622945

    authors： Halkin A,Roth A,Jonas M,Behar S

    更新日期：2001-10-01 00:00:00

  • Reducing catheter-related thrombosis using a risk reduction tool centered on catheter to vessel ratio.

    abstract：:In vascular access practices, the internal vessel size is considered important, and a catheter to vessel ratio (CVR) is recommended to assist clinicians in selecting the most appropriate-sized device for the vessel. In 2016, new practice recommendations stated that the CVR can increase from 33 to 45% of the vessels di...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,评审

    doi：10.1007/s11239-017-1569-y

    authors： Spencer TR,Mahoney KJ

    更新日期：2017-11-01 00:00:00

  • Acquired factor V inhibitors: a systematic review.

    abstract：:The occurrence of an inhibitor against coagulation factor V (FV) is a rare but challenging condition, which may span from asymptomatic laboratory abnormalities to potentially life-threatening bleeding. The onset of FV inhibitors has been associated most frequently in the past with the patients' exposure to topical bov...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,评审

    doi：10.1007/s11239-010-0529-6

    authors： Franchini M,Lippi G

    更新日期：2011-05-01 00:00:00

  • Monitoring the roles of prothrombin activation fragment 1 and 2 (F1 + 2) in patients with atrial fibrillation receiving rivaroxaban and apixaban.

    abstract：:Factor Xa (FXa) inhibitors are recommended for use in fixed doses without laboratory monitoring. However, prior studies reported the importance of establishing biomarkers representing anticoagulation intensity related to bleeding or thrombotic events. To test the hypothesis that prothrombin activation fragment 1 and 2...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-020-02079-7

    authors： Ueno EI,Fujibayashi K,Sawaguchi J,Yasuda Y,Takano S,Fujioka N,Kawai Y,Fujita H,Tanaka Y,Kajinami K

    更新日期：2020-08-01 00:00:00

  • ABO blood group influences transfusion and survival after cardiac surgery.

    abstract：:ABO dependent variation in von Willebrand factor (vWf) and procoagulant factor VIII (FVIII) is a plausible mechanism for modulating perioperative hemostasis and bleeding. Group AB has the highest and group O the lowest vWf and FVIII levels. Therefore, we tested the hypothesis that ABO blood group is associated with pe...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s11239-013-1045-2

    authors： Welsby IJ,Phillips-Bute B,Mathew JP,Newman MF,Becker R,Rao S,Milano CA,Stafford-Smith M

    更新日期：2014-10-01 00:00:00

  • Indications of combined vitamin K antagonists and aspirin therapy.

    abstract：:Based on their mode of action, it is reasonable to expect that the combination therapy of aspirin and a vitamin K antagonist (VKA) may be more beneficial in preventing (athero) thrombotic complications in high-risk patients for cardiovascular events. However, there is no consensus about additional aspirin use in the m...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,评审

    doi：10.1007/s11239-008-0234-x

    authors： Loualidi A,Bredie SH,Janssen MC

    更新日期：2009-05-01 00:00:00

  • Functional testing of tranexamic acid effects in patients undergoing elective orthopaedic surgery.

    abstract：:Tranexamic acid (TXA) can reduce blood loss and transfusion rates in orthopaedic surgery. In this regard, a new viscoelastometric test (TPA-test, ClotPro), enables the monitoring of TXA effects. This prospective observational study evaluated and correlated TXA plasma concentrations (cTXA) following intravenous and ora...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-020-02272-8

    authors： Groene P,Sappel SR,Saller T,Nitschke T,Sa PA,Paulus A,Chappell D,Schäfer ST

    更新日期：2020-09-12 00:00:00

  • Genetic determinants of platelet response to clopidogrel.

    abstract：:Antiplatelet agents are the mainstay treatment in the prevention and management of atherothrombotic complications. However, a substantial interpatient variability in response to clopidogrel has been reported. Furthermore, patients with coronary artery disease and lesser platelet inhibition in response to clopidogrel a...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,评审

    doi：10.1007/s11239-011-0611-8

    authors： Kubica A,Kozinski M,Grzesk G,Fabiszak T,Navarese EP,Goch A

    更新日期：2011-11-01 00:00:00

  • Synchronous cardiocerebral infarction in the era of endovascular therapy: which to treat first?

    abstract：:A cardiocerebral ischemic attack (CCI) or a concurrent acute ischemic stroke (AIS) and myocardial infarction (AMI) is a severe event with no clear recommendations for ideal management because of the rarity of the scenario. The narrow time window for treatment and complexity of the treatment decision puts immense press...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,评审

    doi：10.1007/s11239-017-1484-2

    authors： Yeo LLL,Andersson T,Yee KW,Tan BYQ,Paliwal P,Gopinathan A,Nadarajah M,Ting E,Teoh HL,Cherian R,Lundström E,Tay ELW,Sharma VK

    更新日期：2017-07-01 00:00:00

  • Factors influencing early neurological improvement after mechanical thrombectomy among patients with acute basilar artery occlusion: a single center prospective observational cohort study.

    abstract：:The predictive value of and the influencing factors associated with early neurological improvement (ENI) among patients with acute basilar artery occlusion (BAO) have not been well studied. The present study aimed to evaluate whether ENI predicted a better functional outcome and to identify the influencing factors of ...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-020-02153-0

    authors： Sun X,Zhang H,Tong X,Gao F,Deng Y,Ma G,Ma N,Mo D,Song L,Liu L,Huo X,Miao Z

    更新日期：2021-01-01 00:00:00

  • Osteoprotegerin is not associated with angiographic coronary calcification.

    abstract：UNLABELLED:Coronary artery calcification may play a significant role in the pathophysiology of plaque progression and healing. We hypothesized that osteoprotegerin, an inhibitor of osteoclastogenesis, may participate in the calcification of coronary plaques or the response to injury after coronary stenting. A prospecti...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-006-9026-3

    authors： Gogo PB Jr,Schneider DJ,Terrien EF,Sobel BE,Dauerman HL

    更新日期：2006-12-01 00:00:00

  • Point-of-care testing of coagulation in patients treated with edoxaban.

    abstract：:Edoxaban, alongside other direct oral anticoagulants (DOAC), is increasingly used for prevention of thromboembolism, including stroke. Despite DOAC therapy, however, annual stroke rate in patients with atrial fibrillation remains 1-2%. Rapid exclusion of relevant anticoagulation is necessary to guide thrombolysis or r...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-020-02143-2

    authors： Härtig F,Birschmann I,Peter A,Hörber S,Ebner M,Sonnleitner M,Spencer C,Bombach P,Stefanou MI,Kuhn J,Mengel A,Ziemann U,Poli S

    更新日期：2020-10-01 00:00:00

  • EPC mobilization after erythropoietin treatment in acute ST-elevation myocardial infarction: the REVEAL EPC substudy.

    abstract：:Erythropoietin (EPO) was hypothesized to mitigate reperfusion injury, in part via mobilization of endothelial progenitor cells (EPCs). The REVEAL trial found no reduction in infarct size with a single dose of EPO (60,000 U) in patients with ST-segment elevation myocardial infarction. In a substudy, we aimed to determi...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s11239-013-0944-6

    authors： Povsic TJ,Najjar SS,Prather K,Zhou J,Adams SD,Zavodni KL,Kelly F,Melton LG,Hasselblad V,Heitner JF,Raman SV,Barsness GW,Patel MR,Kim RJ,Lakatta EG,Harrington RA,Rao SV

    更新日期：2013-11-01 00:00:00

  • Role of prothrombin 19911 A>G polymorphism, blood group and male gender in patients with venous thromboembolism: Results of a German cohort study.

    abstract：:The role of the A>G polymorphism at position 19911 in the prothrombin gene (factor [F] 2 at rs3136516) as a risk factor for venous thromboembolism [VTE] is still unclear. To evaluate the presence of the F2 polymorphism in VTE patients compared to healthy blood donors and to adjust the results for common inherited thro...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-020-02169-6

    authors： Limperger V,Kenet G,Kiesau B,Köther M,Schmeiser M,Langer F,Juhl D,Shneyder M,Franke A,Klostermeier UK,Mesters R,Rühle F,Stoll M,Steppat D,Kowalski D,Rocke A,Kuta P,Bajorat T,Torge A,Neuner B,Junker R,Nowak-Göttl

    更新日期：2020-06-27 00:00:00

  • 4G/5G PAI-1 promoter polymorphism and acute-phase levels of PAI-1 following coronary bypass surgery: a prospective study.

    abstract：BACKGROUND AND OBJECTIVE:The 4G/5G plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism has been associated with basal PAI-1 levels, with ischemic heart disease, and with adverse prognosis in critically ill patients. We hypothesized it might also influence the acute-phase levels of PAI-1 following coronary b...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1023/B:THRO.0000024052.79415.62

    authors： Burzotta F,Iacoviello L,Di Castelnuovo A,Zamparelli R,D'Orazio A,Amore C,Schiavello R,Donati MB,Maseri A,Possati G,Andreotti F

    更新日期：2003-12-01 00:00:00

  • Lack of alpha 2-antiplasmin enhances ADP induced platelet micro-aggregation through the presence of excess active plasmin in mice.

    abstract：BACKGROUND:The role of alpha2-antiplasmin (alpha2-AP) on platelet aggregation was investigated using mice deficient in alpha2-AP (alpha2-AP(-/-)) or using wild type mice (alpha2-AP(+/+)). METHODS:Blood samples were taken from each mouse under anesthesia with ether and platelet rich plasma (PRP) was prepared. Platelet ...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1023/a:1025096609558

    authors： Takei M,Matsuno H,Okada K,Ueshima S,Matsuo O,Kozawa O

    更新日期：2002-12-01 00:00:00

  • Ultrastructure of a late-stage bacterial endocarditis valve vegetation.

    abstract：:Infective endocarditis (IE) remains a severe illness with high mortality rate, despite advances in antibiotic therapy and cardiac surgery. If infectious bacteria and platelets are two key players of human IE vegetation developmental process, their interactions and respective roles in fully developed late-stage IE vege...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-020-02232-2

    authors： Baudoin JP,Camoin-Jau L,Prasanth A,Habib G,Lepidi H,Hannachi N

    更新日期：2020-08-04 00:00:00

  • Time to Treatment: A Crucial Factor in Thrombolysis and Primary Angioplasty.

    abstract：:Time to treatment with thrombolytic therapy has been recognized as an important factor in the treatment of patients with acute myocardial infarction: By restoring infarct-related artery patency earlier, clinical outcome is improved. Of the several components of time delay between the onset of pain to opening of the ar...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/BF00181669

    authors： Cannon CP

    更新日期：1996-01-01 00:00:00

  • Stress hyperglycemia is predictive of worse outcome in patients with acute ischemic stroke undergoing intravenous thrombolysis.

    abstract：:No study investigated the possible detrimental effect of stress hyperglycemia on patients affected acute ischemic stroke (AIS) undergoing intravenous thrombolysis (IVT). A new index, the glucose-to-glycated hemoglobin ratio (GAR), has been developed for assessing stress hyperglycemia. We retrospectively analyzed data ...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-020-02252-y

    authors： Merlino G,Smeralda C,Gigli GL,Lorenzut S,Pez S,Surcinelli A,Marini A,Valente M

    更新日期：2020-08-24 00:00:00

  • Challenges and benefits of an inpatient anticoagulation service: one hospital's experience.

    abstract：:While outpatient anticoagulation services (AMS) have existed extensively for a number of years, inpatient AMS have only recently begun to be implemented on a widespread basis. This is in direct response to anticoagulation regulations set forth by entities such as the Joint Commission (TJC) and the Centers for Medicare...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-011-0563-z

    authors： Burnett A,D'Angio R,Earl LE,Garcia D

    更新日期：2011-04-01 00:00:00

  • Microbubble potentiated transcranial duplex ultrasound enhances IV thrombolysis in acute stroke.

    abstract：BACKGROUND:We studied whether 2 MHz transcranial color-coded duplex ultrasound (TCCD), combined with a second generation ECA, accelerate IV rtPA-thrombolysis in the acute phase of MCA stroke more than TCCD monitoring alone. METHODS:Non-randomized acute MCA stroke patients undergoing IV rtPA-thrombolysis and 2 MHZ-TCCD...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 临床试验,杂志文章

    doi：10.1007/s11239-007-0044-6

    authors： Perren F,Loulidi J,Poglia D,Landis T,Sztajzel R

    更新日期：2008-04-01 00:00:00

  • The effect of the REG2 Anticoagulation System on thrombin generation kinetics: a pharmacodynamic and pharmacokinetic first-in-human study.

    abstract：:The REG2 Anticoagulation System consists of pegnivacogin, a subcutaneously administered aptamer factor IXa inhibitor, and its intravenous active control agent, anivamersen. Its effect on thrombin generation is unknown. A prospectively designed thrombin generation study was conducted within the phase 1 ascending dose s...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s11239-014-1081-6

    authors： Vavalle JP,Rusconi CP,Zelenkofske S,Wargin WA,Ortel TL,Alexander JH,Povsic TJ,Becker RC

    更新日期：2014-10-01 00:00:00

  • Repeated early thrombolysis in cervical spinal cord ischemia.

    abstract：:Specific therapy of acute spinal ischemia is not established. We report the first case of an MRI-verified cervical spinal ischemia treated by thrombolysis and review the literature. A 72-year old woman with right-sided motor hemiparesis and trunk ataxia was treated by intravenous thrombolysis with full recovery. Three...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-015-1332-1

    authors： Etgen T,Höcherl C

    更新日期：2016-07-01 00:00:00